|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US8168663||FOLDRX PHARMS||Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof|| |
(2 months from now)
|US7214695||FOLDRX PHARMS||Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding|| |
(6 months from now)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7214696||FOLDRX PHARMS||Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding|| |
(2 months from now)
|US8653119||FOLDRX PHARMS||Methods for treating transthyretin amyloid diseases|| |
(3 months from now)
Vyndaqel is owned by Foldrx Pharms.
Vyndaqel contains Tafamidis Meglumine.
Vyndaqel has a total of 4 drug patents out of which 0 drug patents have expired.
Vyndaqel was authorised for market use on 03 May, 2019.
Vyndaqel is available in capsule;oral dosage forms.
Vyndaqel can be used as treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm).
Drug patent challenges can be filed against Vyndaqel from 2023-05-04.
The generics of Vyndaqel are possible to be released after 03 May, 2026.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Chemical Entity Exclusivity (NCE)||May 3, 2024|
|Orphan Drug Exclusivity (ODE)||May 3, 2026|
NCE-1 date: 2023-05-04
Market Authorisation Date: 03 May, 2019
Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic